# Wockhardt (NSE: WOCKPHARMA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/WOCKPHARMA · Pivot · prices to 21 Oct 2026

Wockhardt (NSE: WOCKPHARMA) closed at ₹1,871.50 on 21 Oct 2026. With a market capitalisation of ₹32,678 Cr, it ranks 240th by market cap among the 3,928 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 4.3% in FY26. Its 52-week range is ₹1,086.70 (23 Mar 2026) to ₹2,422.30 (1 Jun 2026); the last close is 22.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹965 Cr (+29.9% year on year) and net profit ₹164 Cr, on a consolidated basis. Promoters held 49.08% of the company as of 30 Jun 2026; 14.68% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,871.50 |
| Market cap | ₹32,678 Cr |
| ROE | 4.3% (FY26) |
| ROCE | 7.7% (FY26) |
| Debt to equity | 0.43 |
| 52-week high | ₹2,422.30 (1 Jun 2026) |
| 52-week low | ₹1,086.70 (23 Mar 2026) |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹965 Cr | +29.9% | ₹164 Cr | — | ₹10.23 |
| Q3 FY26 | ₹888 Cr | +23.2% | ₹61 Cr | +205.0% | ₹3.61 |
| Q2 FY26 | ₹782 Cr | −3.3% | ₹82 Cr | — | ₹4.81 |
| Q1 FY26 | ₹738 Cr | −0.1% | −₹108 Cr | — | −₹5.33 |
| Q4 FY25 | ₹743 Cr | +6.1% | −₹45 Cr | — | −₹1.57 |
| Q3 FY25 | ₹721 Cr | +2.9% | ₹20 Cr | — | ₹0.91 |
| Q2 FY25 | ₹809 Cr | +7.4% | −₹16 Cr | — | −₹1.47 |
| Q1 FY25 | ₹739 Cr | +14.8% | −₹16 Cr | — | −₹0.95 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹3,012 Cr | −₹57 Cr |
| FY24 | ₹2,798 Cr | −₹472 Cr |
| FY23 | ₹2,651 Cr | −₹621 Cr |
| FY22 | ₹3,230 Cr | −₹279 Cr |
| FY21 | ₹2,708 Cr | ₹689 Cr |
| FY20 | ₹2,844 Cr | −₹43 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 49.08%
- Foreign institutions: 7.22%
- Domestic institutions: 9.24%
- Non-institutions: 34.44%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Ajanta Pharma](https://app.pivotnow.in/stock/AJANTPHARM) | — | ₹38,295 Cr | — | — |
| [Narayana Hrudayalaya](https://app.pivotnow.in/stock/NH) | — | ₹38,156 Cr | — | — |
| [Gland Pharma](https://app.pivotnow.in/stock/GLAND) | — | ₹36,274 Cr | — | — |
| [Global Health](https://app.pivotnow.in/stock/MEDANTA) | — | ₹34,013 Cr | — | — |
| [Krishna Institute of Medical Sciences](https://app.pivotnow.in/stock/KIMS) | — | ₹32,181 Cr | — | — |
| [Procter Gamble](https://app.pivotnow.in/stock/PGHH) | — | ₹30,105 Cr | — | — |

## Questions and answers

### What is the share price of Wockhardt today?

Wockhardt (NSE: WOCKPHARMA) last closed at ₹1,871.50 on 21 Oct 2026. Its 52-week high is ₹2,422.30 and its 52-week low is ₹1,086.70.

### What is the market cap of Wockhardt?

Wockhardt's market capitalisation is ₹32,678 Cr (₹32,678 Cr) at the — close, ranking 240th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Wockhardt?

Return on equity was 4.3% in FY26 and return on capital employed was 7.7% in FY26 (consolidated figures).

### Is Wockhardt a debt-free company?

No. Wockhardt's debt-to-equity ratio was 0.43 in FY26, with total debt of ₹1,518 Cr.

### What were Wockhardt's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Wockhardt reported revenue of ₹965 Cr, +29.9% year on year, and net profit of ₹164 Cr.

### What is the shareholding pattern of Wockhardt?

As of 30 Jun 2026: promoters 49.08%, foreign institutions 7.22%, domestic institutions 9.24%, non-institutions 34.44%. 14.68% of promoter shares were pledged.

### Who are Wockhardt's competitors?

The listed Pharma & Healthcare companies closest to Wockhardt by market cap are Ajanta Pharma, Narayana Hrudayalaya, Gland Pharma, Global Health, Krishna Institute of Medical Sciences and Procter Gamble.

### Is Wockhardt a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Wockhardt's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on WOCKPHARMA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.